For twenty years the answer to why can’t Medicare pay for this has been a sentence written in 2003, at a moment when the available weight-loss drugs were marginal and obesity was widely treated as a lifestyle failing rather than a disease.
The sentence is still there. What has changed is the machinery built around it.
What was agreed, in outline
Three moving parts, and it is worth keeping them separate because they benefit different people.
Negotiated pricing. Lower agreed prices for federal programmes, framed against what these drugs cost in comparable wealthy countries — a benchmark under which the United States has always paid several times more.
A direct-purchase channel. Cash prices below list, sold directly rather than through the pharmacy benefit chain. This is the part most likely to matter to an uninsured or excluded patient today.
A Medicare pilot. A limited route to coverage for obesity indications, operating alongside rather than instead of the statutory exclusion.
Who this actually helps
Uninsured and cash-paying patients. The clearest beneficiaries. A price several hundred dollars below list is the difference between treatment and no treatment for a large number of people.
Medicare beneficiaries with obesity and no qualifying second condition. The group most comprehensively failed by the current design. Whether the pilot reaches them depends entirely on eligibility criteria and on whether their plan participates.
Nobody with good commercial coverage. If your copay is thirty dollars, none of this is for you. Cash prices are not competing with a functioning benefit.
Announcing a price is not the same as a person being able to buy at it. The distance between those two things is measured in eligibility criteria.
The questions the announcement does not answer
- Who qualifies. BMI thresholds, comorbidity requirements, prior-therapy requirements. These decide the size of the affected population and they are set administratively.
- Whether plans participate. A pilot that plans may join is a different thing from a benefit they must offer.
- What happens at the end. Pilots expire. Nobody starting a chronic treatment should be relying on a time-limited programme without knowing what follows it.
- Supply. A price that increases demand does nothing if manufacturing cannot meet it, which is the constraint that has governed this market from the start.
What to do about it now
Do not stop an existing arrangement that works while waiting for a new one to arrive. That is the single most common way people end up with a gap in treatment.
If you are uninsured or excluded, price the direct-purchase route against whatever you are currently paying, including compounded product — for some people it is now competitive with the gray market, which is the most consequential quiet effect of the whole thing.
And if you are on Medicare, call your Part D plan and ask two specific questions: whether it is participating, and which GLP-1 products sit on its formulary under which indications. General news coverage cannot answer either.
Then start a record, if you do not have one. Pilots come with eligibility criteria, and eligibility criteria are satisfied with documentation — dated weights, doses, comorbidities, what happened when treatment was interrupted. People who already have twelve months of that in Zenday or a spreadsheet will qualify for things that people relying on memory will not.
The part worth remembering
None of this repeals the exclusion. A future administration can narrow a pilot far more easily than Congress can rewrite a statute, and the underlying position — that American obesity drug pricing is set by negotiation rather than by structure — has not changed.
Useful. Fragile. Worth using while it is there, and worth not building a decade-long treatment plan on top of.